MAPT Haploid H1b and the Damage of BBB in Dorsal Medulla Oblongata and Autonomic Dysfunction in PD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study mainly explored the relationship between the permeability of the blood-brain barrier in the dorsal medulla oblongata and autonomic dysfunction, and the relationship and mechanism of MAPT genotype on the permeability of the blood-brain barrier and the progression of autonomic dysfunction in PD patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Correlation of Reduction of Levodopa and Non-motor Symptoms of Parkinson's Disease After Deep Brain Stimulation

NCT05901350

Parkinson Disease Visual Impairment

COMPLETED NA

Unilateral GPi vs Unilateral STN DBS in the Same Patient With PD

NCT04255719

Parkinson Disease Deep Brain Stimulation Globus Pallidus Interna +1 more

COMPLETED NA

Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET

NCT02039024

Parkinson's Disease

COMPLETED PHASE2

DBS and SCS Therapy Improve Motor Function in Multiple System Atrophy With Predominant Parkinsonism

NCT04617873

Multiple System Atrophy, Parkinson Variant (Disorder)

UNKNOWN NA

Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders

NCT00001178

Alzheimer's Disease Dementia Down's Syndrome

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

According to the MDS 2015 clinical diagnostic criteria for Parkinson's disease and the diagnostic criteria for autonomic dysfunction (AutD), the patients were divided into PD with AutD group and PD without AutD group. DCE results, pet-pdrp+18f-dopa data and clinical evaluation (SCOPA-AUT, HRV and sleep EEG) were analyzed; Blood samples were collected to detect MAPT gene polymorphism, oligomers and phosphorylated synuclein. To explore the relationship between the permeability of the blood-brain barrier in the dorsal medulla oblongata and autonomic dysfunction, and the relationship and mechanism of MAPT genotype on the permeability of the blood-brain barrier and the progression of autonomic dysfunction in PD patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PD with AutD

Parkinson's disease with autonomic dysfunction

Autonomic dysfunction

Intervention Type OTHER

Autonomic dysfunction

PD without AutD

Parkinson's disease without autonomic dysfunction

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autonomic dysfunction

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meet the diagnostic criteria for idiopathic PD of MDS 2015
* Age ≥ 45 years old
* Be able to complete various clinical evaluations and scales; Willing to participate in MRI, no contrast agent allergy

Exclusion Criteria

* Dementia was diagnosed before or 1 year after the onset of motor symptoms
* Single gene form of PD
* Coexisting neuropathological diagnosis considered to affect PD progression
* Known complications affecting BBB (severe infection, cerebral infarction, etc.
* Such as comorbidities known to affect the autonomic nervous system (e.g., diabetes gangliopathy or neuropathy)
* Disturbance of consciousness, serious cerebral hemorrhage or cerebral thrombosis, serious brain tumor or brain surgery history, serious mental illness or other serious nervous system diseases, which are enough to seriously interfere with the subjects' motor and non motor symptoms
* According to the judgment of the researcher, the researcher is unable to complete the research test according to the requirements of the research scheme.

Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No